Susquehanna Fundamental Investments, LLC Corvus Pharmaceuticals, Inc. Transaction History

Susquehanna Fundamental Investments, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	BUY	$1.46 - $2.48 $20,133 - $34,199	13,790 New	13,790 $23,000
Q1 2021 May 17, 2021	SELL	$2.86 - $4.77 $121,412 - $202,496	-42,452 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$3.56 - $4.86 $41,566 - $56,745	-11,676 Reduced 21.57%	42,452 $151,000
Q3 2020 Nov 16, 2020	BUY	$2.6 - $5.37 $140,732 - $290,667	54,128 New	54,128 $217,000

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $223M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.